Mabion

Bloomberg: MAB PW Equity, Reuters: MABP.WA

Sell, PLN 17

Downgraded from: Hold



One step forward, two steps back

Recent problems with obtaining EMA approval for MabionCD20 and the decision to run an additional Phase I/II clinical trial 1) postponed the potential launch of the drug candidate to 2024, 3) deteriorated its sales potential, 2) triggered additional costs and 4) increased the risk of termination of the deal with Mylan. With that in mind, we are downgrading our recommendation for Mabion to SELL and cut our TP to PLN 17/share, which implies 47% downside potential.

MabionCD20 in Europe: additional costs and reduced sales potential

In our view, the decision to run another Phase I/II clinical trial postpones the potential registration of MabionCD20 in Europe to 2024 and entails additional costs of over PLN 100m. By that time, the EU rituximab market should be already played-out by Mabion's competitors. We reduce the company's target market share in Europe to 6% (from 8% previously) and still assume 8% market share in the less crowded US market.

Is Mylan still in the game?

Mylan has an option to terminate the partnering deal with Mabion (and request PLN 42m of advances to be paid back by the Polish company) which will be activated at the beginning of 2021. Our valuation of MabionCD20 for Mylan suggests that the probability of such a scenario is relatively high. This poses a significant risk to the project and associated future milestone payments.

Too early to value the Covid-19 vaccine project

In September, Mabion signed a memorandum of understanding with an Australian developer of the Covid-19 vaccine, Vaxine Pty. At this stage, we forbear from including the project into our valuation as: 1) the signing of the final agreement depends on the result of the mutual due-diligence process, 2) Vaxine's project is in Phase 1 clinical trial, and is still awaiting the first efficacy data, and 3) the success of more advanced projects (Pfizer, AstraZeneca, Moderna) may largely meet the demand for subsequent vaccines.


Loans from shareholders provide only a short breather


The loans of up to PLN 30m offered recently by the main shareholders should give Mabion a short breather, and we expect the company to report PLN 28m cash at the end of 3Q20. However, total cash needs by the time of receiving EMA approval (exp. 4Q23) may amount to as much as 155m, which suggests that the issue of up to 1.91m shares planned by the management may not be enough to meet the company's needs.

PLN mn	2018	2019	2020F	2021F	2022F
Revenues	0	0	0	0	2
EBITDA	-52	-51	-47	-53	-50
EBIT	-63	-62	-58	-63	-59
Net profit	-67	-63	-62	-64	-61
P/E	nm	nm	nm	nm	nm
P/BV	34.3	-50.6	-5.2	-3.0	-2.1
EPS	-4.91	-4.57	-4.51	-4.67	-4.44
DPS	0.00	0.00	0.00	0.00	0.00
FCF	-	-	-59	-60	-57
CAPEX	7	9	5	5	5

F - forecast by PKO BP Securities

Key data		
Market price (PLN)		31.80
Upside		-47%
No. of shares (mn)		13.73
Market Cap (PLNmn)		436.62
Free float		55%
Free float (PLNmn)		242
Free float (USDmn)		64
EV (PLNmn)		-
Net debt (PLNmn)		55.36
Dividend		
Div yield		0.0%
Ex-div		-
Major Shareholders	% (of shares
Twiti Investments		17.33
Generali OFE		13.11
Maciej Wieczorek		11.85
Polfarmex		10.47
Previous recomm.	Date & tar	get price
Hold	29-04-20	23.00
Hold	19-02-20	65.00







	WIG	Company
1 month	-3.5%	-12.6%
3 months	-4.4%	27.2%
6 months	10.0%	43.9%
12 months	-14.0%	-61.2%
Min 52 weeks PLN		17.96
Max 52 weeks PLN		103.60
Av. turnover/day PLN mn		1.76

Analyst

Dawid Górzyński +48 22 521 97 69 dawid.aorzunski@pkobp.pl

Address:

PKO BP Securities ul. Puławska 15

02-515 Warszawa

This recommendation was drafted against remuneration at the individual request of The Warsaw Stock Exchange (Giełda Papierów Wartościowych w Warszawie S.A.). The Warsaw Stock Exchange holds proprietary copyright to this recommendation.



VALUATION - what has changed in our model?

DCF assumptions:

- Risk-free rate was cut to 2.0% from 2.5% previously
- Equity risk premium (6%) and beta (2.0x) were kept intact

P&L forecasts:

- MabionCD20 market share in Europe was reduced to 6% (from 8% previously) due to the decision to run an additional Phase I/II clinical trial. Market share in the US was unchanged (10%)
- Milestone payments from Mylan (total USD 30m) were postponed to 2023-24F (from 2021-22F)
- Success rates of both EU registrations (50%) and US registrations (30%) were kept unchanged
- Total costs of delivering MabionCD20 to the market were increased by over PLN 70m

DCF model											
PLN mn	2020F	2021F	2022F	2023F	2024F	2025F	2026F	2027F	2028F	2029F 2	2029F<
EBIT	-58.1	-63.0	-59.2	5.0	70.4	71.4	71.5	82.3	81.9	81.4	
Tax rate	0.0	0.0	0.0	0.8	10.6	10.7	10.7	12.3	12.3	12.2	
NOPLAT	-58.1	-63.0	-59.2	4.3	59.8	60.7	60.8	70.0	69.6	69.2	69.2
CAPEX	4.7	5.0	5.0	5.0	50.0	50.0	20.0	10.0	10.0	10.0	17.3
Depreciation	11.3	10.2	9.4	8.7	8.1	14.8	20.4	20.4	18.7	17.3	17.3
Changes in working capital	7.3	2.0	2.0	-5.7	14.8	11.7	11.8	2.2	0.0	0.0	2.0
FCF	-58.7	-59.8	-56.8	13.6	3.1	13.8	49.4	78.2	78.3	76.6	67.2
WACC	13.9%	13.4%	12.8%	12.4%	12.4%	12.4%	12.4%	12.1%	11.9%	11.6%	11.4%
Discount ratio	0.00	0.89	0.79	0.70	0.63	0.56	0.50	0.46	0.41	0.38	
DFCF	0.0	-53.0	-45.0	9.6	2.0	7.7	24.9	35.7	32.5	29.0	
Growth in Phase II	0.0%										
DFCF Sum - Phase I	43.3										
DFCF Sum - Phase II	223.9										
Enterprise Value (EV)	267.2										
Net debt	55.4										
Minorities	0.0										
Fair value	212										
Number of shares (million)	13.7										
Fair value per share as at 31.12.2020	15.4										
Target price in 12 mths (PLN)	17.0										
Current price	31.8										
Expected rate of return	-47%										

Source: forecasts of PKO BP Securities



WACC											
	2020F	2021F	2022F	2023F	2024F	2025F	2026F	2027F	2028F	2029F	2029F<
Risk-free rate	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%
Equity premium	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%
Beta	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
Debt risk premium	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%
Tax rate	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%
Equity cost	14.0%	14.0%	14.0%	14.0%	14.0%	14.0%	14.0%	14.0%	14.0%	14.0%	14.0%
Debt cost	8.5%	8.5%	8.5%	8.5%	8.5%	8.5%	8.5%	8.5%	8.5%	8.5%	8.5%
Weight of equity	97%	88%	79%	71%	71%	71%	71%	66%	61%	57%	52%
Weight of debt	3%	12%	21%	29%	29%	29%	29%	34%	39%	43%	48%
WACC	13.9%	13.4%	12.8%	12.4%	12.4%	12.4%	12.4%	12.1%	11.9%	11.6%	11.4%

Source: forecasts of PKO BP Securities

Sensitivity

		Growth in Phase II									
		-1.0%	-0.5%	0.0%	0.5%	1.0%					
	10.0%	18.0	19.0	20.0	21.0	22.0					
WACC	11.0%	16.0	17.0	18.0	<u>19.0</u>	20.0					
WACC	11.4%	16.0	16.0	17.0	<u>18.0</u>	19.0					
	12.0%	15.0	15.0	16.0	<u>17.0</u>	18.0					
	13.0%	14.0	14.0	15.0	15.0	16.0					

Source: PKO BP Securities



Financial Forecasts

Profit and loss account		2016	2017	2018	2019	2020F	2021F	2022F	2023F
Sales of products, goods and materials	-	0	0	0	0	0	0	2	61
Costs of sold products, goods and materials	-	0	0	0	0	0	0	0	0
Gross profit on sales	-	0	0	0	0	0	0	2	60
EBITDA	-	-49	-54	-52	-51	-47	-53	-50	14
General administrative expenses	-	14	21	21	24	19	18	18	19
Other operating costs	-	3	2	3	3	0	0	0	0
Operating profit	-	-56	-62	-63	-62	-58	-63	-59	5
Financial expenses net	-	0	4	-4	0	-4	-1	-2	-2
Pre-tax profit	-	-56	-58	-67	-63	-62	-64	-61	3
Income tax	-	0	0	0	0	0	0	0	1
Net Profit (loss)	-	-56	-58	-67	-63	-62	-64	-61	3
Balance Sheet		2016	2017	2018	2019	2020F	2021F	2022F	2023F
Fixed assets	-	68	72	73	73	66	60	56	52
Intangible assets	-	0	0	0	1	1	1	1	1
Tangible assets	-	68	72	72	72	64	59	54	51
Other long-term assets	-	0	0	0	0	0	0	0	0
Current assets	-	23	10	72	40	18	21	30	37
Inventories	-	4	7	10	9	12	16	20	20
Receivables	-	4	2	3	3	4	4	7	2
Cash and cash equivalents	-	15	1	58	28	2	1	2	14
Other short-term assets	-	0	0	1	1	1	1	1	1
Total Assets	-	91	82	145	114	84	82	86	90
Equity capital	-	4	-54	42	-22	-83	-148	-209	-206
Liabilities	-	88	137	103	135	167	229	294	295
Long-term liabilities	-	14	16	36	49	84	144	204	204
Loans and borrowings	-	0	4	3	4	39	99	159	159
Trade liabilities and other	-	14	12	33	45	45	45	45	45
Short-term liabilities	-	73	120	67	86	83	85	90	91
Loans and borrowings	-	13	62	2	18	18	18	18	18
Prepayments	-	44	36	44	44	44	44	44	44
Trade liabilities and other	-	17	22	20	24	21	23	28	29
Total Equity & Liabilities	-	91	82	145	114	84	82	86	90
Cash flow statement		2016	2017	2018	2019	2020F	2021F	2022F	2023F
Cash flow on operating activity	-	-15	-54	-39	-34	-58	-56	-54	17
Cash flow on investment activity	-	-2	-7	-7	-9	-5	-5	-5	-5
Cash flow on financial activity	-	26	47	103	12	35	60	60	0
Indicators (%)		2016	2017	2018	2019	2020F	2021F	2022F	2023F
ROE	-	-		1,121.0%	-610.1%	117.8%	55.5%	34.2%	-1.4%
Net Debt		-2.1	65.0	-52.8	-6.0	55.4	116.3	174.9	162.6

Source: forecasts of PKO BP Securities

		CONTACTS	
Equity Research			
Emil Łobodziński	(Investment Advisor)	(+4822) 521 89 13	emil.lobodzinski@pkobp.pl
Paweł Małmyga	(technical analysis)	(+4822) 521 65 73	pawel.malmyga@pkobp.pl
Przemysław Smoliński	(technical analysis)	(+4822) 521 79 10	przemyslaw.smolinski2@pkobp.pl
Dawid Górzyński	(pharmaceuticals)	(+4822) 521 97 69	dawid.gorzynski@pkobp.pl
Strategic Individual Clients De	epartment		
Paweł Kodym	(director)	(+4822) 521 80 14	pawel.kodym@pkobp.pl
Michał Petruczeńko		(+4822) 521 79 69	michal.petruczenko@pkobp.pl
Ewa Kalinowska		(+4822) 521 79 88	ewa.kalinowska.2@pkobp.pl
Grzegorz Klepacki		(+4822) 521 78 76	grzegorz.klepacki@pkobp.pl
Joanna Makowska		(+4822) 342 99 34	joanna.makowska@pkobp.pl
Jacek Gaszewski		(+4822) 342 99 28	jacek.gaszewski@pkobp.pl
Ewald Wyszomirski		(+4822) 521 78 39	ewald.wyszomirski@pkobp.pl
Przemysław Lasota		(+4822) 580 33 14	przemyslaw.lasota@pkobp.pl
Tomasz Zabrocki		(+4822) 521 82 13	tomasz.zabrocki@pkobp.pl

CONTACTS

INFORMATION AND RESERVATIONS

REGARDING THE NATURE OF RECOMMENDATION AND LIABILITY FOR ITS DRAFTING, CONTENTS AND DISTRIBUTION

This recommendation (hereinafter: "Recommendation") has been drafted by PKO BP Securities (hereinafter "PKO BP Securities"), the recommending entity (hereinafter: "Recommending Entity"), acting in conformity with the Polish Act on Trading in Financial Instruments of 29 July 2005 and the Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest, solely for the purposes of the customers of PKO BP Securities and is subject to confidentiality within seven calendar days of its distribution date.

This recommendation was drafted against remuneration at the individual request of The Warsaw Stock Exchange (Giełda Papierów Wartościowych w Warszawie S.A.). The Warsaw Stock Exchange holds proprietary copyright to this recommendation.

Whenever this Recommendation mentions an "Issuer", it will be understood as a company to which the Recommendation pertains directly or indirectly. If the Recommendation pertains to more than one company, the term "Issuer" will apply to all these companies.

The perspective expressed in the Recommendation reflects the opinion of the Analyst(s) of PKO BP Securities regarding the analysed company and the financial instruments issued by The Perspective expression in the recommendation reflects the optimion of the Analysics of record by the Issuer. The Recommendation has been prepared subject to due diligence and reliability, based on facts and information generally considered credible (including, in particular, financial statements

and current reports of the company); nevertheless, PKO BP Securities does not guarantee their absolute precision or completeness. The basis for preparing the Recommendation comprises information on the company which was publicly available by the day of its drafting. The forecasts presented are based solely on the analysis conducted by PKO BP Securities and on a number of assumptions which may prove incorrect in the future. PKO BP Securities does not grant any assurance that the forecast presented will be proved right. PKO BP Securities is not liable for any losses incurred as a result of decisions made on the basis of information contained in this Recommendation. PKO Securities as a professional entity does not evade liability for an imprecise or incomplete product or for the losses incurred by the Customer as a result of investment decisions taken on the basis of an unreliable Recommendation. PKO Securities will bear no liability if the Recommendation has been prepared with due diligence and thoroughness. PKO Securities will not be held liable for any potential defects of the recommendation, in particular for its incompleteness or imprecision, if said defects could not be avoided or foreseen at the moment of undertaking standard actions in drafting the Recommendation. In the future, PKO BP Securities may issue other recommendations, presenting other conclusions which are consistent with those contained in this Recommendation. Such recommendations reflect various assumptions, points of view and analytical methods adopted by the analysts preparing them. PKO BP Securities hereby announces that the accuracy of earlier recommendations is no guarantee of their accuracy in the future.

PKO BP Securities hereby announces that investing money in financial instruments is connected with the risk of losing a part of or all the invested funds. PKO BP Securities notes that the price of financial instruments is influenced by many different factors which are or may be independent from the Issuer or the results of the Issuer's operations. These can include, among other things, changing economic, legal, political and fiscal conditions. A decision on purchasing any financial instruments should be made solely on the basis of the prospectus, offer or other generally available documents and materials published in accordance with the binding provisions of Polish law.

This Recommendation does not constitute an offer or an invitation to subscribe for or purchase or conclude transactions on financial instruments and is not aimed at encouraaina its addressees to purchase or sell any financial instruments.

With the exception of the remuneration paid by PKO BP Securities, Analysts do not receive any other consideration from the Issuer or other third parties for drafting recommendations. Analysts drafting recommendations are remunerated on a variable basis, indirectly depending on the financial results of PKO BP Securities that may be contingent, among other things, on the results generated by PKO BP Securities with respect to brokering services offered.

PKO BP Securities hereby announces that it renders brokering services in the scope of drafting investment analyses, financial analyses and other recommendations of a general nature under a permit of the Polish Financial Supervision Authority dated 7 October 2010. At the same time, PKO BP Securities hereby announces that brokering services are rendered to customers in accordance with the binding "Rules and regulations for rendering the service of drafting investment analyses, financial analyses and publications regarding financial instruments by PKO BP Securities" (here) as well as on the basis of a written agreement on rendering the service of drafting investment analyses, financial analyses and publications regarding financial instruments by PKO BP Securities. The entity exercising supervision over PKO BP Securities within the scope of its brokering operations is the Polish Financial Supervision Authoritu

Explanation of the specialist terminology used

min (max) 52 weeks: minimum (maximum) of the market share price during the previous 52 weeks Capitalisation: product of the share market price and the number of shares

EV: sum of the company's capitalisation and net debt

Free float (%): share of the total number of shares decreased by 5% stakes held by one shareholder and own shares held by the company in the total number of shares Average trading/month: average trading per month calculated as total trading value over previous 12 months divided by 12

ROE: rate of return on equity

ROA: rate of return on assets

EBIT: operating profit

EBITDA: operating profit + depreciation and amortization

EPS: earnings per share DPS: dividend per 1 share CEPS: sum of net profit and depreciation and amortization per 1 share P/E: quotient of share market price and EPS P/BV: quotient of share market price and book value of one share EV/EBITDA: quotient of capitalisation increased by the company's net debt and EBITDA Gross sales margin: relation of gross sales profit to net sales proceeds EBITDA margin: relation of the sum of operating profit and depreciation to net sales proceeds EBIT margin: relation of operating profit to net sales proceeds Net profitability: relation of net profit to net sales proceeds

Valuation methods applied

A PKO BP Securities recommendation is based on at least two out of four valuation methods: DCF (discounted cash flow model), ratio analysis method (comparing the values of basic market ratios with similar ratios of other companies representing a given sector), sum of the parts of assets method (SOTP) and discounted dividends model. A disadvantage of the DCF and the discounted dividends model is their high sensitivity to adopted assumptions, including, in particular, those pertaining to determining the residual value. Furthermore, the discounted dividends model cannot be applied to the valuation of companies without a determined dividend policy. The advantages of both these methods include their independence from current market valuations of peer companies. On the other hand, the advantage of the ratio analysis is the fact that it is based on a measurable market valuation of a given sector. Its disadvantage lies in the risk that at any given time, the market might not value peer companies correctly. The sum of the parts method (SOTP) consists in summing up the values of various assets of the company, calculated using one of the above methods.

Recommendations applied by PKO BP Securities

A BUY recommendation means that the recommendation author thinks that company shares have the potential for at least a 10% price growth.

A HOLD recommendation means that the recommendation author thinks that company shares have the potential for growth between 0 and a 10%.

A SELL recommendation means that the recommendation author thinks that company shares have the potential for a price decline. A recommendation may be assigned an "UNDER REVIEW" rating, which means that the recommendation ceases to be binding for an unexpected reason and that PKO BP Securities is conducting investment research aimed at its update. Said investment research will result in issuing a new recommendation.

A recommendation may be assigned a "SUSPENDED" rating, which means that PKO BP Securities stopped conducting investment research. After investment research is recommenced, the latest issued Recommendation will become binding.

Recommendations issued by PKO BP Securities are binding for a period of 12 months from their issue, unless they are updated in the meantime. PKO BP Securities updates issue recommendations depending on the market situation and the analysts' subjective opinion. The frequency of such updates is not specified.

Connections which could influence the objectivity of recommendations

Entities associated with PKO BP Securities may, insofar as is legally permissible, participate or invest in financial transactions in relations with the Issuer, render services to or assist in rendering services to the Issuer or have the option to or conclude transactions on financial instruments issued by the Issuer ("financial instruments"). PKO BP Securities may, insofar as permissible under Polish law, conclude transactions on financial instruments before this instrument is presented to recipients.

PKO BP Securities has the following connections with the Issuer:

Issuer:	Reservation
Mabion	-

Explanations:

1.

3

4. 5

6

During the previous 12 months, PKO BP Securities was party to agreements on offering financial instruments issued by the Issuer or connected with assessing financial instruments issued by the Issuer. During the previous 12 months, PKO BP Securities was a member of a consortium offering financial instruments issued by the Issuer.

PKO BP Securities purchases and sells financial instruments issued by the Issuer in its own name, in order to perform service or investment underwriting agreements.

PKO BP Securities has the role of market animator for the Issuer's financial instruments under the terms stipulated in the Regulations of the Warsaw Stock Exchange.

PKO BP Securities has the role of the Issuer's animator for the Issuer's financial instruments under the terms stipulated in the Regulations of the Warsaw Stock Exchange. PKO BP Securities and PKO Bank Polski, whose organisational unit is PKO BP Securities, are parties to an agreement on drafting recommendations with the Issuer.

PKO BP Securities and PKO Bank Polski, whose organisational unit is PKO BP Securities, hold shares of the Issuer, which are the object of this recommendation, in a total number constituting at least 5% of share capital.

It is possible that PKO BP Securities or PKO Bank Polski or persons involved in drafting a report have a long or short position on the Issuer's shares or other instruments whose value is connected with the value of the financial instruments issued by the Issuer in an amount not lower than 0.5% of the Issuer's share capital.

Excluding the above, no other contractual relations exist between the Issuer and BM PKO BP that could influence the objectivity of this Recommendation.

Disclosures

The recommendation has not been disclosed to the Issuer.

Other disclosures

No person involved in preparing the report or any of their next of kin hold any functions on the governing bodies of the Issuer or a managerial position in the Issuer's organisation and no such person or their next of kin are party to any agreement with the Issuer concluded under the terms different from other agreements concluded between the Issuer and consumers. There are no people holding shares in the Issuer or financial instruments whose value is connected in any significant manner with the value of financial instruments issued by the Issuer among persons involved in drafting the recommendation or persons who were not involved in drafting it, but who had or could have access to it.

PKO Bank Polski, its subsidiaries, representatives or employees may occasionally conclude transactions or be interested in purchasing financial instruments of companies which are indirectly or directly connected with the analysed company.

PKO BP Securities is bound by internal regulations managing conflicts of interests; in particular, these regulations determine internal organisational solutions and limitations regarding information flow to prevent uncontrolled information flow between respective organisational entities or PKO BP Securities' employees in order to prevent and avoid conflicts of interests regarding recommendations; in particular, the Chinese wall procedure has been implemented. The internal organisational structure of PKO BP Securities ensures that respective kinds of brokering operations are executed separately.

This Recommendation has been drafted subject to due diligence to the best knowledge of the Recommending Entity; there exist no other connections between PKO BP Securities and the analyst drafting this Recommendation on one part and the Issuer on the other.

The time and date stipulated on the front page of the report are the time and date of completing the process of drafting the Recommendation.

The time and date of the first distribution of the Recommendation are identical with the time and date of delivering this Recommendation in electronic form to customers.



Whenever this Recommendation quotes a price for the financial instrument, it will be understood as the closing price from the last trading day.

The list below sets out all the recommendations drafted by PKO BP Securities in the last 12 months, within the scope of the "Analytic Coverage Support Pilot Programme".

Company	Recommendatio n	Date of reco.	Target price	Relevant Market	Market cap.		P/E		P/E EV/EBITDA				Analyst
Company	Recommendation	Dute offeco.	idi get price	Price*	(PLN mn)	2018	2019F	2020F	2018	2019F	2020F	Analyst	
Asseco SEE	Trzymaj	2019-11-19	25,00	23,8	2387,1	9,5	10,0	21,2	4,0	7,3	10,7	Małgo rzata Żelazko	
ZE PAK	Trzymaj	2019-12-04	7,80	7,4	543,6	nm	nm	nm	5,1	1,3	5,0	Andrzej Rembelski	
Apator	Trzymaj	2019-12-05	22,5	21,10	602,9	10,7	13,1	9,9	7,0	6,5	6,4	Piotr Łopaciuk	
Mabion	Кир иј	2019-12-16	100,00	60,2	436,6	nm	nm	nm	0,00	0,00	0,0	Dawid Górzyński	
Asseco SEE	Trzymaj	2020-03-16	27,20	25	2387,1	9,5	10,0	21,2	4,0	7,3	10,7	Małgo rzata Żelazko	
ZE PAK	Sprzedaj	2020-04-24	6,50	7,66	543,6	nm	nm	nm	5,1	1,3	5,0	Andrzej Rembelski	
Apator	Trzymaj	2020-04-29	19,5	19,00	570,7	10,7	13,1	9,4	7,0	6,5	6,1	Piotr Łopaciuk	
Mabion	Trzymaj	2020-04-29	23	22,80	436,6	nm	nm	nm	0,0	0,0	0,0	Dawid Górzyński	
Asseco SEE	Trzymaj	2020-06-03	41	40,40	2387,1	9,5	10,0	21,2	4,0	7,3	10,7	Małgo rzata Żelazko	
MLP Group	Кир иј	2020-07-31	95	72,50	1249,8	8,6	6,5	7,2	21,2	27,4	25,3	Pio tr Zyb ała	
Asseco SEE	Trzymaj	2020-08-25	48,5	48,40	2387,1	9,5	10,0	21,2	4,0	7,3	10,7	Małgo rzata Żelazko	
Apator	Trzymaj	2020-09-18	21,5	21,20	570,7	10,7	13,1	9,4	7,0	6,5	6,1	Piotr Łopaciuk	
ZE PAK	Trzymaj	2020-10-01	10,2	10,00	543,6	nm	nm	nm	5,1	1,3	5,0	Andrzej Rembelski	
Mabion	Sell	2020-10-13	17	31,80	436,6	nm	nm	nm	0,0	0,0	0,0	Dawid Górzyński	

*at the time of publication